Trial reportHaematologica2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Trial
- GNA15 induces drug resistance in B cell acute lymphoblastic leukemia by promoting fatty acid oxidation via activation of the AMPK pathway.Molecular and cellular biochemistry · 2025Article
- Review
- Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.Cancer medicine · 2024Article
- Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia.Haematologica · 2024Review
- Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia.Frontiers in immunology · 2023Review
- PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.Science advances · 2022Article
- Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?Clinical hematology international · 2022Review
- Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.Immune network · 2022Review
- Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2022Review
- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.Cancer treatment and research · 2022Article
- MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?Hematology. American Society of Hematology. Education Program · 2021Article
- Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System.Clinical lymphoma, myeloma & leukemia · 2021Article
- The landscape of bispecific T cell engager in cancer treatment.Biomarker research · 2021Review
- CAR T cells better than BiTEs.Blood advances · 2021Article
- Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges.Paediatric drugs · 2020Review
- Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.Bone marrow transplantation · 2020Article
- T cell-engaging therapies - BiTEs and beyond.Nature reviews. Clinical oncology · 2020Review
- Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.European journal of haematology · 2020Article
- Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy.Blood and lymphatic cancer : targets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.